A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aciex Therapeutics, Inc.
• Treatments: Cetirizine

Criteria

Inclusion Criteria:

• positive bilateral conjunctival allergen challenge (CAC)reaction

Exclusion Criteria:

• known contraindications or sensitivities to the study medication or its components

• any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters

• use of disallowed medication during the period indicated prior to the enrollment or during the study